BioSpace News Archive

Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be held today at 8:00 a.m. Eastern Time

Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2021, prior to the market open on Thursday, May 6, 2021. Company management will host a conference call and webcast to discuss its financial results

Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as evidenced by its initiation of a phased U.S. commercial launch of MYCAPSSA® as the first oral therapy for treatment of acromegaly, today announced financial results for the first quarter ended March 31, 2021

- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced a clinical development update for CERPASS, its registration-directed global randomized Phase 2 clinical trial of RP1 in combination with Libtayo® (cemiplimab)

Genesis Software Innovations “GSI,” a company that has created an innovative foundational platform solution in the orthopedic space, announced today that they have received FDA clearance for their PreView™ 3D Shoulder Arthroplasty Planning Software

Pharmaceutical industry veteran Joe Jimenez appointed Board Chair Cynthia Butitta joins as Independent Director

On track to achieve 2021 guidance Webcast today, May 5, 2021, at 11:30 a.m. Eastern Time

-- Achieved $3.3 Million in Net Revenue in First Quarter -- -- Launched EYSUVIS® and Expanded Commercial Coverage to More than 69 Million Commercial Lives -- -- New Credit Facility Provides up to $125M -- -- Cash Runway Projected for at Least Two Years -- -- Conference Call and Webcast at 8:00 a.m. ET --

Q1 2021 revenue growth of 30.8% year-over-year, organic revenue growth of 23.8% Q1 2021 GAAP EPS of $0.37; non-GAAP EPS of $0.44, compared to $0.14 in Q1 2020 Raising fiscal year 2021 outlook on strong demand for the Company’s high-performance life science tools, scientific instruments and diagnostic solutions

DUBLIN, Ireland, and Boston MA, May 5, 2021, Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, provides a business update and announces unaudited financial results for the first quarter ended March 31, 2021.